Search research articles
Contact Us
Filters
Showing results (111-120 of 222) with videos related to
Page
of 23
Sort By:
Gynecologic Oncology
|
December 24, 2018
Variation in resource utilization associated with the surgical management of ovarian cancer
J Alejandro Rauh-Hain, Michael K Hidrue, Peter Gaccione, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 22, 2013
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era
Carien L Creutzberg, Henry C Kitchener, Michael J Birrer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2010
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial
Daniela Matei, Michael W Sill, Heather A Lankes, et al.
Gynecologic Oncology
|
March 2, 2010
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus
Warner K Huh, Michael W Sill, Kathleen M Darcy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2014
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer
Elizabeth Pham, Michael J Birrer, Scott Eliasof, et al.
International Journal of Clinical Oncology
|
November 7, 2022
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors
Susana Campos, Ursula Matulonis, Suzanne Berlin, et al.
Gynecologic Oncology Reports
|
September 5, 2020
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]
Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2006
Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance
Fred W Wamunyokoli, Tomas Bonome, Ji-Young Lee, et al.
Gynecologic Oncology
|
April 9, 2020
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
Rebecca C Arend, Hannah M Beer, Yael C Cohen, et al.
Cancers
|
November 25, 2018
ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression
Tsz-Lun Yeung, Ching Chou Tsai, Cecilia S Leung, et al.
Page
of 23
Search research articles
Search
Showing results (111-120 of 222) with videos related to
Sort By:
Page
of 23
Gynecologic Oncology
|
December 24, 2018
Variation in resource utilization associated with the surgical management of ovarian cancer
J Alejandro Rauh-Hain, Michael K Hidrue, Peter Gaccione, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 22, 2013
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era
Carien L Creutzberg, Henry C Kitchener, Michael J Birrer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2010
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial
Daniela Matei, Michael W Sill, Heather A Lankes, et al.
Gynecologic Oncology
|
March 2, 2010
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus
Warner K Huh, Michael W Sill, Kathleen M Darcy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2014
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer
Elizabeth Pham, Michael J Birrer, Scott Eliasof, et al.
International Journal of Clinical Oncology
|
November 7, 2022
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors
Susana Campos, Ursula Matulonis, Suzanne Berlin, et al.
Gynecologic Oncology Reports
|
September 5, 2020
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]
Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2006
Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance
Fred W Wamunyokoli, Tomas Bonome, Ji-Young Lee, et al.
Gynecologic Oncology
|
April 9, 2020
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
Rebecca C Arend, Hannah M Beer, Yael C Cohen, et al.
Cancers
|
November 25, 2018
ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression
Tsz-Lun Yeung, Ching Chou Tsai, Cecilia S Leung, et al.
Page
of 23